Gontivimab clinical trials
Also written ALX-0171.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2011
How each study uses gontivimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ALX-0171
- 4
Studies by the year they started
7 studies that test it; most in 2013 (2)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Studies
Open first, then newest update. How each study uses gontivimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Dose Ranging Study of ALX-0171 in Infants Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract InfectionCompletedPhase 2Ablynx, a Sanofi companyNCT02979431Written as ALX-0171 3.0 mg/kg
- Evaluation of ALX-0171 in Japanese Children Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract InfectionTerminatedPhase 2Ablynx, a Sanofi companyNCT03418571Written as ALX-0171 1.5 mg/kg
- Efficacy and Safety of ALX-0171 in Adult Hematopoietic Stem Cell Transplant (HSCT) Recipients Who Present With Respiratory Syncytial Virus (RSV) InfectionWithdrawnPhase 2Ablynx, a Sanofi companyNCT03468829Written as ALX-0171 Dose 1
- A Multicentre Study in Otherwise Healthy Infants and Toddlers Hospitalised For and Diagnosed With RSV Lower Respiratory Tract Infection to Evaluate the Safety, Tolerability, and Clinical Activity of ALX-0171CompletedPhase 1/2Ablynx, a Sanofi companyNCT02309320Written as ALX-0171
- ALX-0171 Phase I Pharmacokinetic Study in Healthy Male VolunteersCompletedPhase 1Ablynx, a Sanofi companyNCT01875926Written as ALX-0171
- ALX-0171 Safety Study in Adults With Hyperresponsive AirwaysCompletedPhase 1Ablynx, a Sanofi companyNCT01909843Written as ALX-0171
- ALX-0171 Phase I Study, Evaluating Single Ascending Dose and Multiple Dose in Healthy Male VolunteersCompletedPhase 1Ablynx, a Sanofi companyNCT01483911Written as ALX-0171
Codes
What other systems call gontivimab · ClinicalTrials.gg INT001514
- MeSH (NLM) C000712591gontivimabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) DY8W536BUYGONTIVIMABConfirmed FDA, NLM
- NCI Thesaurus C156058GontivimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000712591 | gontivimab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | DY8W536BUY | GONTIVIMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C156058 | Gontivimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.